Conference

Contact us


Speaker Introduction

Kaixian Chen
Academician,Shanghai Institute of Materia Medica,Chinese Academy of Sciences

Hualiang Jiang

Jing Cheng
Academician of Chinese Academy of Engineering

Subject
The fourth generation of drug-eluting coronary stents

Junbo Ge

Yongkui Sun

Subject
Artificial intelligence capsule gastroscope Robot

Zhaokun Li

Subject
Pathogens and Research and Development of New Drugs

Zihe Rao

Subject
Research Progress in the Non-clinical Safety Evaluation of Immunotherapeutic Drugs

Yan Huo
Director of Toxicology Department, National Center for Safety Evaluation of Drugs,National Institutes for Food and Drug Control

Subject
Integration and Quality Management of Human Genetic Resources in General Hospital Biobank

KANG Xiaonan
Executive director of Biobank

Subject
Informatics Challenges in the Precision Health Initiative

Kun Huang

Subject
A Case Study of Contamination Control in a Biopharmaceutical Manufacturing Plant

Michael Ahern
Head of School of Science & Computing, Technological University Dublin

Subject
Systems Biologics: The Next Therapeutic Revolution

Sachdev Sidhu
The Donnelly Centre, University of Toronto

Vladimir L. Katanaev
Full Professor in Translational Oncology, Department of Cell Physiology and Metabolism, Translational Research Centre in Oncohaematology, Faculty of Medicine, University of Geneva

WANG Hualiang

Subject
The concept of endovascular therapy for intracranial aneurysm

Jianmin Liu

Subject
Orthopaedic Robot

Huiwu Li

Jiatao Lou

Subject
Health economics (HTA evaluation of medical devices)

Xiaohua Ying

Subject
Applying deep learning and AI to drug discovery at MSD

Alan Cheng
默沙东研究实验室 计算与结构化学部主任

Subject
China's Clinical Biobank /Human Genetic Resources Enter the Age of Standardization and Recognition

GAO Hengjun

Subject
Combining Machine Learning and Structural Modeling for Drug Discovery

JIANWEI (JOHN) CHE
Lead Scientist, Dana-Farber Cancer Institute, Dept. of Cancer Biology, Harvard Medical School Present
Independent Consultant for drug discovery companies 2018/08-2019/01
Chief Technology Officer & Co-founder, M3 Bioinformatics & Technology, Inc. 2014/10-2018/10
Visiting scholar, Dept. of Chem. & Biochem., UCSD 2015/1-2019/01
Sr. Research Investigator (2009-2014), Research Investigator (2001-2009) 2001/01-2014/10
Genomics Institute of the Novartis Research Foundation

Subject
“Shock and Kill” for HIV Cure

LIU Jian
Principal Scientist, Discovery Chemistry, Merck Sharp & Dohme

Wansheng Jerry Liu
Partner & Chair of China Practice, Fox Rothschild LLP

XIA Mingde

Xiaole Shen
Senior Scientist, Celgene Corporation

Subject
Smart Insulin — Glycoengineering Confers Glucose Responsivity on Insulin

Lin Yan
Principal Scientist, Merck & Co., Inc.

WU Yusheng
Tetranov Pharmaceutical Co., LTD

Beier Yao

Subject
Platform technology

Hongbing He

Hui Feng

Subject
The Practical Exploration and normalization construction of biobanking of human genetic resources

YANG Yajun
Fudan University Associate professor ,School of Life Sciences

Subject
The Application of Superparamagnetic Particle Imaging (SPI) Technology in IVD

Yu Ge
CEO, Mars Sciences LLC
Yu Ge have been involved in research and development of new drug and medical diagnostics for almost 30 years. I’ve worked at several drug discovery companies in various R&D and leadership capacities. Currently, I serve as the CEO of Mars Sciences, a medical diagnostic company. In drug discovery, I worked mainly in 3 disease areas: cardiovascular, cancer, and diabetes, and took 5 compounds into clinical trials. I am an inventor/co-inventor on 67 patents and authored over 20 peer reviewed scientific papers. In medical diagnostics, I’ve led the company to successfully develop the world leading Superparamagnetic Particle Imaging (SPI) technology and build the world’s first diagnostic instrument based on SPI technology (SPI Analyzer). SPI Analyzer, HY-POC Chips, and Mobile Mars APP formed the basis of MARS Smart Diagnostic Platform, which is currently being commercialized.

Subject
Introduction of National Standard System of Chinese Biobanks And inter-laboratory comparison

ZHANG Xiaoyan
head of biobank National Engineering Center for Biochip at Shanghai

Andre Ivacinco

FU Qihua

Subject
Accelerating Drug Discovery with Physics Based Modeling and Artificial Intelligence

Jianxin Duan
德国Schrodinger公司 研究员

Subject
Agile Project Management and Operation Excellence in the New Age of Drug Development

John Sun
Global Program Lead, Novartis

Li Jia
中组部“千人计划”特聘教授;福建省肿瘤转移药物干预重点实验室 主任

Subject
Driving Clinical Strategy & Optimized Design with RWD and Clinical Patient-level Data

Meng Fu
Vice President of Clinical Development, 3D Medicine

PAN Boshen

阿尔谢尼耶夫

诺维科夫 鲍里斯

亚历山大 嘎拉甘

叶烈娜

中国代表

Subject
Shanghai Malignant Tumor Clinical Biobank /Human Genetic Resources Alliance

SUN Menghong

Li Mengjie

Jianxin Xu

Xiaodong Chen
Senior Research Investigator, Drug Product Development Team Leader, Bristol-Myers Squibb

Subject
Patenting Antibody Based Inventions in The US

Puknys Erik
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Subject
Licensee system policy on software product licenses (3D printing (joint))

XiJian Medical Company

Yaoping Ruan
Chief Data Scientist, LinkDoc 2018 – present,
RSM, Senior Manager, STSM, IBM Watson Health 2005 – 2018

Zhihua Xiao

Subject
Orthopedic joint localization

WENG Zixin

XU Jiaqi

Huaxing Zhu

Jin Wang

Kang Li
Associate Professor, New Jersey Medical School, Rutgers University

Subject
Domestic pacemakers

Li Wang

Subject
Integrated CT linear accelerator

Zhong Ouyang

Subject
Domestic medical equipment consumables or stent applications

Shanghai PUYI Biotechnology Co.,Ltd

Subject
A novel therapy targeting a survival mechanism of cancer cells

ZENG Qingping
Founder and CEO of Fosun Orinove PharmaTech Inc

Subject
The role of small molecules in targeted therapies for cancer_Current status and the future

ZHAO Xingdong
Fochon Pharmaceuticals

Guanshan Zhu

Subject
Artificial Intelligence: Real Solutions in Drug Development

Wei Ding
CSO, Admera Health

TOP